Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ecole Polytechnique Fédérale de Lausanne | OTHER |
Not provided
Not provided
Not provided
Not provided
The objective of this research project is to determine the impact on brain HEP metabolites and fluxes of an oral consumption of a commercially available nutrition product (Peptamen® 1.5 vanilla) in healthy volunteers.
Therefore, we intend to perform 31P-MRS before and after oral intake of the nutrition product.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| nutrition product | Other | Peptamen® 1.5 Vanilla, orally administration |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Peptamen® 1.5 vanilla | Other | Administration orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| 31P metabolites | The change in concentration of brain 31P metabolites | 31P metabolites and fluxes will be measured during one hour 2 times, one before product intake (control) and the second one 45 min after product intake" |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Known type 1 or type 2 diabetes, on anamnesis
Family history of type 2 diabetes (parents)
Any other metabolic disease possibly impacting the postprandial glucose and insulin response (on anamnesis, to the opinion of the medical expert)
Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease, etc
Any history of neurological / psychological disease (meningitis, epilepsy), to the opinion of the investigator
Claustrophobia
Hearing disorders
Any medication impacting dietary fat absorption and metabolism like statins, bile acid sequestrants, lipid lowering medications, or fibrates , to the opinion of the medical expert
Pregnancy (on anamnesis) and/or lactation
Having any metallic, electronic, magnetic, or mechanical implants, devices, or objects, for safety reason linked to magnetic field exposure (MRS):
Subject injured by a metallic object or foreign body
History of cancer within the past year
Allergy or intolerance to any food or compound used
Currently following a strict exercise program (minimum three times per week) in order to either lose weight, gain muscle or reach competition standards for a chosen sport
Currently participating or having participated in a clinical trial during the past month
Subjects not willing and/or not able to comply with scheduled visits and the requirements of the research protocol. Subject having a hierarchical link with the investigator or co-investigators.
Subject who cannot be expected to comply with the research protocol.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maurice Beaumont, MD | Société des Produits Nestlé (SPN) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Metabolic Unit, Clinical Development Unit, Nestec | Lausanne | 1000 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided